|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Böhm B, Schwenk W, Hucke HP and Stock W:
Does methodic long-term follow-up affect survival after curative
resection of colorectal carcinoma? Dis Colon Rectum. 36:280–286.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jung WB, Yu CS, Lim SB, Park IJ, Yoon YS
and Kim JC: Anastomotic recurrence after curative resection for
colorectal cancer. World J Surg. 41:285–294. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
McGregor JR, Galloway DJ, McCulloch P and
George WD: Anastomotic suture materials and implantation
metastasis: An experimental study. Br J Surg. 76:331–334. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Costi R, Santi C, Bottarelli L, Azzoni C,
Le Bian AZ, Ricco M, Sarli L, Silini EM and Violi V: Anastomotic
recurrence of colon cancer: Genetic analysis challenges the widely
held theories of cancerous cells' intraluminal implantation and
metachronous carcinogenesis. J Surg Oncol. 114:228–236. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vakiani E, Shah RH, Berger MF,
Makohon-Moore AP, Reiter JG, Ostrovnaya I, Attiyeh MA, Cercek A,
Shia J, Lacobuzio-Donahue CA, et al: Local recurrences at the
anastomotic area are clonally related to the primary tumor in
sporadic colorectal carcinoma. Oncotarget. 8:42487–42494. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Okada S, Hata K, Kawai K, Yamomoto Y,
Tanaka T, Nishikawa T, Sasaki K, Kaneko M, Emoto S, Murono K and
Nozawa H: Association between KRAS G13D mutations and anastomotic
recurrence in colorectal cancer: Two case reports. Medicine
(Baltimore). 98:e147812019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brierley JD, Gospodarowicz MK and
Wittekind C: UICC TNM classification of malignant tumours. 8th
edition. Wiley-Blackwell; Oxford: 2017
|
|
9
|
Do H and Dobrovic A: Dramatic reduction of
sequence artefacts from DNA isolated from formalin-fixed cancer
biopsies by treatment with uracil- DNA glycosylase. Oncotarget.
3:546–558. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Andreyev HJ, Norman AR, Cunningham D,
Oates JR and Clarke PA: Kirsten ras mutations in patients with
colorectal cancer: The multicenter ‘RASCAL’ study. J Natl Cancer
Inst. 90:675–684. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roth AD, Tejpar S, Delorenzi M, Yah P,
Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C,
et al: Prognostic role of KRAS and BRAF in stage II and III
resected colon cancer: Results of the translational study on the
PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 28:466–474.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hinoi T: Cancer genomic profiling in
colorectal cancer: Current challenges in subtyping colorectal
cancers based on somatic and germline variants. J Anus Rectum
Colon. 5:213–228. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Watanabe T, Yoshino T, Uetake H, Yamazaki
K, Ishiguro M, Kurokawa T, Saijo N, Ohashi Y and Sugihara K: KRAS
mutational status in Japanese patients with colorectal cancer:
Results from a nationwide, multicenter, cross-sectional study. Jpn
J Clin Oncol. 43:706–712. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kadowaki S, Kakuta M, Takahashi S,
Takahashi A, Arai Y, Nishimura Y, Yatsuoka T, Ooki A, Yamaguchi K,
Matsuo K, et al: Prognostic value of KRAS and BRAF mutations in
curatively resected colorectal cancer. World J Gastroenterol.
21:1275–1283. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Passiglia F, Bronte G, Bazan V, Galvano A,
Vincenzi B and Russo A: Can KRAS and BRAF mutations limit the
benefit of liver resection in metastatic colorectal cancer
patients? A systematic review and meta-analysis. Crit Rev Oncol
Hematol. 99:150–157. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Inoue Y, Saigusa S, Iwata T, Okugawa Y,
Toiyama Y, Tanaka K, Uchida K, Mohri Y and Kusunoki M: The
prognostic value of KRAS mutations in patients with colorectal
cancer. Oncol Rep. 28:1579–1584. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bazan V, Migliavacca M, Zanna I, Tubiolo
C, Grassi N, Latteri MA, La Farina M, Albanese I, Dardanoni G,
Salerno S, et al: Specific codon 13 K-ras mutations are predictive
of clinical outcome in colorectal cancer patients, whereas codon 12
K-ras mutations are associated with mucinous histotype. Ann Oncol.
13:1438–1446. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hayama T, Hashiguchi Y, Okamoto K, Okada
Y, Ono K, Shimada R, Ozawa T, Toyoda T, Tsuchiya T, Iinuma H, et
al: G12V and G12C mutations in the gene KRAS are associated with a
poorer prognosis in primary colorectal cancer. Int J Colorectal
Dis. 34:1491–1496. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Imamura Y, Morikawa T, Liao X, Lochhead P,
Kuchida A, Yamauchi M, Qian ZE, Nishihara R, Meyerhardt JA, Haigis
KM, et al: Specific mutations in KRAS codons 12 and 13, and patient
prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer
Res. 18:4753–4763. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kodaz H, Hacibekiroglu I, Erdogan B,
Turkmen E, Tozkir H, Albayrak D, Uzunoglu S and Cicin I:
Association between specific KRAS mutations and the
clinicopathological characteristics of colorectal tumors. Mol Clin
Oncol. 3:179–184. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Organ SL, Hai J, Radulovich N, Marshall
CB, Leung L, Sasazuki T, Shirasawa S, Zhu CQ, Navab R, Ikura M and
Tsao MS: p120RasGAP is a mediator of rho pathway activation and
tumorigenicity in the DLD1 colorectal cancer cell line. PLoS One.
9:e861032014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stolze B, Reinhart S, Bulllinger L,
Frohling S and Scholl C: Comparative analysis of KRAS codon 12, 13,
18, 61, and 117 mutations using human MCF10A isogenic cell lines.
Sci Rep. 5:85352015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Margonis GA, Kim Y, Sasaki K, Samaha M,
Amini N and Pawlik TM: Codon 13 KRAS mutation predicts patterns of
recurrence in patients undergoing hepatectomy for colorectal liver
metastases. Cancer. 122:2698–2707. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
De Roock W, Jonker DJ, Di Nicolantonio F,
Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M,
Piessevaux H, et al: Association of KRAS p.G13D mutation with
outcome in patients with chemotherapy-refractory metastatic
colorectal cancer treated with cetuximab. JAMA. 304:1812–1820.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tejpar S, Celik I, Schlichting M,
Sartorius U, Bokemeyer C and Van Cutsem E: Association of KRAS G13D
tumor mutations with outcome in patients with metastatic colorectal
cancer treated with first-line chemotherapy with or without
cetuximab. J Clin Oncol. 30:3570–3577. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rowland A, Dias MM, Wiese MD, Kichenadasse
G, McKinnon RA, Karapetis CS and Sorich MJ: Meta-analysis comparing
the efficacy of anti-EGFR monoclonal antibody therapy between KRAS
G13D and other KRAS mutant metastatic colorectal cancer tumours.
Eur J Cancer. 55:122–130. 2016. View Article : Google Scholar : PubMed/NCBI
|
